Skip to content
Back to feed
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedSubjects not reportedSystematic reviewPublished in a peer-reviewed journal

Review of Lithium and Electroconvulsive Therapy Effects on Disease Modification in Various Studies

A systematic review found that lithium and electroconvulsive therapy provided the most substantial evidence as interventions that may modify disease progression. However, it does not present original data.

Most relevant to
—
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Human efficacy
Not established from this source
Mechanism
Not reported
Evidence strength
Not graded
Outcome
Not reported

Why it matters

This review highlights potential therapeutic avenues for disease modification, emphasizing the need for future studies to focus on outcomes reflecting disease progression rather than just symptom relief.

What this does not prove

The review does not provide original research data and emphasizes the need for future trials to change focus for meaningful results.

Next milestone

No next milestone was established from the available source.

Study facts
Study design
Systematic review
Participants / samples
Not reported
Randomised
Not reported
Controlled
Not reported
Primary endpoint met
Not reported
Relevant MS type
Not reported
Publication date
2026-10-26
Evidence reviewed
Abstract only
Regulatory approval
Not reported
Research areas
Not classified
Biological target
Not reported
Pathway
Not reported
Population
Not reported
Size of effect
Not reported
Secondary endpoints
Not reported
MRI endpoints
Not reported
Biomarkers
Not reported
Safety
Not reported

Original sources

Supporting passages (5)
publication datePublication date: 2026-10-26
study designPublication types: Journal Article
findingsLithium and electroconvulsive therapy showed the greatest evidence as disease-modifying interventions.
limitationsHowever, to establish this and identify potential other disease-modifying treatments, there needs to be a shift in the focus of psychiatric clinical trials to include primary outcomes that reflect disease progression and not just acute symptom burden.
peer reviewedPublication types: Journal Article

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.

0

Discussion 0 comments

Log in or join to comment.